THORChain has released version 3.21.0 to fix issues that halted trading of Solana (SOL) and Zcash (ZEC) on its network. The update addresses a new Solana transaction type that disrupted SOL trading and a matching error that paused ZEC trading without causing fund loss. It also repairs affiliate fee payments, fixes a vulnerability in Rujira's FIN contract, and resolves a bug causing network state growth and paused limit swaps. The upgrade introduces dynamic pricing to prevent spam in swap registration and a new streaming yield feature for bond providers. Monero (XMR) support remains pending for a future update. The network upgrade is scheduled for October 23 at block 28,366,100.
THORChain's upcoming upgrade to restore SOL and ZEC trading is presented here with a snapshot of Pluang's cryptocurrency market as of Oct 20, 2026 01:32 WIB. Among 50 major cryptocurrencies, 41 rose and 8 fell today. Notably, SNX trades at Rp3.868 with a 3.51% gain but shows a heavy 99% sell order activity, contrasting with LTC priced at Rp1.075.679 and a similar 3.49% rise but with more balanced sell/buy activity at 73%/27%. GRT, at Rp428 and up 3.04%, also shows predominantly sell orders at 84%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
